Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Identification of cromolyn sodium as an anti-fibrotic agent targeting both hepatocytes and hepatic stellate cells
Joon‐Seok Choi, Jun Ki Kim, Yoon Jung Yang, et al.
Pharmacological Research (2015) Vol. 102, pp. 176-183
Closed Access | Times Cited: 18

Showing 18 citing articles:

A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial
Surinder S. Birring, Marlies Wijsenbeek, Sanjay Agrawal, et al.
The Lancet Respiratory Medicine (2017) Vol. 5, Iss. 10, pp. 806-815
Open Access | Times Cited: 111
Mast Cells in Liver Fibrogenesis
Ralf Weiskirchen, Steffen K. Meurer, Christian Liedtke, et al.
Cells (2019) Vol. 8, Iss. 11, pp. 1429-1429
Open Access | Times Cited: 48
Mast cells and the gut-liver Axis: Implications for liver disease progression and therapy
Bhagyalakshmi Nair, Adithya Jayaprakash Kamath, Vinay Tergaonkar, et al.
Life Sciences (2024) Vol. 351, pp. 122818-122818
Closed Access | Times Cited: 6
Anti-fibrotic Effects of Synthetic Oligodeoxynucleotide for TGF-β1 and Smad in an Animal Model of Liver Cirrhosis
Jung‐Yeon Kim, Hyun‐Jin An, Woon‐Hae Kim, et al.
Molecular Therapy — Nucleic Acids (2017) Vol. 8, pp. 250-263
Open Access | Times Cited: 42
Phase 2B Study of Inhaled RVT-1601 for Chronic Cough in Idiopathic Pulmonary Fibrosis: A Multicenter, Randomized, Placebo-controlled Study (SCENIC Trial)
Fernando J. Martínez, Marlies Wijsenbeek, Ganesh Raghu, et al.
American Journal of Respiratory and Critical Care Medicine (2022) Vol. 205, Iss. 9, pp. 1084-1092
Closed Access | Times Cited: 19
Research progress in the role and mechanism of Cadherin-11 in different diseases
Xinyi Chen, Hongjiao Xiang, Shiyu Yu, et al.
Journal of Cancer (2021) Vol. 12, Iss. 4, pp. 1190-1199
Open Access | Times Cited: 27
Lyotropic liquid crystalline nanoparticles for oral delivery: formulation and evaluation of sustained-released cromolyn sodium loaded cubosomes
Linh Đinh, Dong‐Min Kim, Ga‐Won Lee, et al.
Journal of Pharmaceutical Investigation (2024) Vol. 54, Iss. 4, pp. 539-554
Closed Access | Times Cited: 3
Isolation and characterization of hepatic mast cells from cholestatic rats
Laura Hargrove, Allyson Graf‐Eaton, Lindsey Kennedy, et al.
Laboratory Investigation (2016) Vol. 96, Iss. 11, pp. 1198-1210
Open Access | Times Cited: 25
Mast cells in liver disease progression: An update on current studies and implications
Linh Pham, Lindsey Kennedy, Leonardo Baiocchi, et al.
Hepatology (2021) Vol. 75, Iss. 1, pp. 213-218
Open Access | Times Cited: 16
Recruitment or activation of mast cells in the liver aggravates the accumulation of fibrosis in carbon tetrachloride-induced liver injury
Mingkang Zhang, Jinru Yang, Yufan Yuan, et al.
Molecular Immunology (2024) Vol. 170, pp. 60-75
Closed Access | Times Cited: 2
CDH11 promotes liver fibrosis via activation of hepatic stellate cells
Wanyuan Ruan, Runsang Pan, Xiaoxu Shen, et al.
Biochemical and Biophysical Research Communications (2018) Vol. 508, Iss. 2, pp. 543-549
Closed Access | Times Cited: 19
Protective effect of lodoxamide on hepatic steatosis through GPR35
So‐Yeon Nam, Soo‐Jin Park, Dong‐Soon Im
Cellular Signalling (2018) Vol. 53, pp. 190-200
Closed Access | Times Cited: 15
Lodoxamide Attenuates Hepatic Fibrosis in Mice: Involvement of GPR35
Mi‐Jeong Kim, Soo‐Jin Park, So‐Yeon Nam, et al.
Biomolecules & Therapeutics (2019) Vol. 28, Iss. 1, pp. 92-97
Open Access | Times Cited: 11
Cromolyn sodium and masitinib combination inhibits fibroblast‐myofibroblast transition and exerts additive cell‐protective and antioxidant effects on a bleomycin‐induced in vitro fibrosis model
Azize Yasemin Göksu Erol, Hülya Dirol, Fatma Gonca Koçancı
Pharmacology Research & Perspectives (2024) Vol. 12, Iss. 5
Open Access | Times Cited: 1
Determination of p K a constants of hypericin in aqueous solution of the anti-allergic hydrotropic drug Cromolyn disodium salt
Peter Keša, Marián Antalı́k
Chemical Physics Letters (2017) Vol. 676, pp. 112-117
Closed Access | Times Cited: 9
The Investigation of Therapeutic Implications of Mast Cell Stabilizer Cromolyn Sodium on Cholestasis and Cholestatic Pruritus in Experimental Cholestasis
Hanife Yurdakul Ertan, Günnur Özbakış Dengiz, Figen Barut, et al.
The Turkish Journal of Gastroenterology (2022) Vol. 34, Iss. 1, pp. 62-72
Open Access | Times Cited: 1
Corrigendum to “Identification of cromolyn sodium as an anti-fibrotic agent targeting both hepatocytes and hepatic stellate cells” [Pharmacol. Res. 102 (2015) 176–183]
Joon‐Seok Choi, Jun Ki Kim, Yoon Jung Yang, et al.
Pharmacological Research (2016) Vol. 110, pp. 277-278
Closed Access
Drug Repurposing Patent Applications July–September 2022
Hermann AM Mucke
Assay and Drug Development Technologies (2022) Vol. 20, Iss. 8, pp. 359-366
Closed Access
Page 1

Scroll to top